To further explore whether CacyBP inhibition can improve the therapeutic effect of immunotherapy, we used the TIDE algorithm [39] to predict the correlation between CacyBP expression and the anti-PD-1 response in HCC patients. The gene discussed is CACYBP; the disease is hepatocellular carcinoma.